Roche Taiwan (Pharma + Diagnostics)

Roche Taiwan is consistently a top-3 MNC pharma in Taiwan by Rx revenue (frequently #1 or #2 alongside Pfizer/MSD) — DOMINANT in oncology with the strongest specialist/KOL relationships in TW oncology of any MNC. Roche pioneered targeted therapy and Roche-Genentech oncology heritage is core brand equity. Roche Pharma Taiwan (台灣羅氏大藥廠) and Roche Diagnostics Taiwan (台灣羅氏醫療診斷設備) operate as separate entities under Roche Holding. Taiwan Rx DTC restricted (藥事法); consumer spend is (a) corporate brand 'Doing now what patients need next' platform, (b) unbranded disease-awareness (HER2 breast cancer testing, MS Day, hemophilia awareness, AMD/wet-AMD awareness), (c) patient association partnerships (Taiwan Breast Cancer Foundation, MS Society Taiwan, TW Hemophilia Association, TW Macular Society), (d) HCP/medical congress sponsorship. Roche Diagnostics has separate consumer footprint via Accu-Chek (OTC self-monitoring blood glucose — diabetes consumers). Estimated NT$300-500M ad spend across Pharma + Dx, mid-tier.